Pay in 4 interest-free payments of $6.88 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
Trial REIMAGINE 2 Phase 3 Duration Reported 2026 Population (N) Adults with T2D Key Result Sponsor reported HbA1c reduction of 1.91 percentage points and 14.2% weight loss
Conclusions and Recommendations Key messages for at-risk populations: The EVOKE trial failure does not invalidate GLP-1 agonists for preventionthe epidemiological signal remains strong, and these drugs may provide metabolic and cardiovascular benefits with potential cognitive co-benefits when used for approved indications SS-31s approval establishes precedent for mitochondrial-targeted therapeuticswatch this space for expanded indications Popular biohacker peptides (BPC-157, Dihexa, P21) have essentially no human cognitive evidence
Why is FDA evaluating BPC-157 against ulcerative colitis when most BPC-157 use is for tendon and tissue repair
Both the average length of the hydrocarbon chain (18.4 carbon atoms) and number of double bonds (1.5) of the fatty acid tails were matched to equivalent experimental values (18.4 and 1.5, respectively) 3
& Du, Q
US$ 21.23
US$ 26.76
US$ 29.27
US$ 29.44
